Michael G Fradley1, Mohammed Alomar2, Marcus W Kilpatrick3, Bernadette Shields2, Nhi Tran2, Amey Best3, Erika Bianco3, Merna Armanious2, R Ashton Vautier2, Kevin Kip4, Theresa M Beckie5, Roohi Ismail-Khan2. 1. Cardio-Oncology Center of Excellence, Division of Cardiology, Department of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. Michael.fradley@pennmedicine.upenn.edu. 2. Cardio-Oncology Program, Moffitt Cancer Center, University of South Florida College of Medicine, Tampa, USA. 3. Exercise Science Program, College of Arts and Sciences, University of South Florida, Tampa, USA. 4. Department of Clinical Analytics, Health Sciences Division, University of Pittsburgh, Pittsburgh, USA. 5. College of Nursing, University of South Florida, Tampa, USA.
Abstract
OBJECTIVE: Women with breast cancer (BCA) and cardiovascular disease (CVD) risk factors are at increased risk of developing cardiovascular complications when exposed to potentially cardiotoxic cancer therapy. The benefit of aggressive CVD risk factor modification to reduce adverse treatment-related psychologic and biologic effects is not well established. METHODS: Using a single group pre-test, post-test design, 33 women with BCA receiving anthracycline and/or trastuzumab therapy participated in a 6-month comprehensive CVD risk reduction program involving formal cardio-oncology evaluation along with regular motivational counseling for improved nutrition and physical activity. Study parameters were assessed at baseline and 6 months with paired t-tests used to evaluate changes after the intervention. RESULTS: The mental component summary score assessed by SF-36V2 improved significantly after program completion (45.0 to 48.8, effect size 0.37, p = 0.017), however the physical component summary score declined (46.2 to 40.9, effect size - 0.53, p = 0.004). Despite this decline in perceived physical health, markers of health-related fitness and nutritional status were maintained or improved. Systolic and diastolic blood pressure also improved after the intervention (136.7 to 124.1 mmHg, p = 0.001 and 84.0 to 78.7 mmHg, p = 0.031, respectively). No significant change in resting heart rate, body mass index, lipids, hemoglobin A1C, or left ventricular ejection fraction was observed. CONCLUSIONS: Patient-reported mental health improved significantly in women with BCA enrolled in a comprehensive CVD risk reduction program despite exposure to potentially cardiotoxic therapies. This study provides preliminary data for future randomized controlled trials evaluating the effects CVD risk reduction program in high-risk breast cancer cohorts.
OBJECTIVE:Women with breast cancer (BCA) and cardiovascular disease (CVD) risk factors are at increased risk of developing cardiovascular complications when exposed to potentially cardiotoxic cancer therapy. The benefit of aggressive CVD risk factor modification to reduce adverse treatment-related psychologic and biologic effects is not well established. METHODS: Using a single group pre-test, post-test design, 33 women with BCA receiving anthracycline and/or trastuzumab therapy participated in a 6-month comprehensive CVD risk reduction program involving formal cardio-oncology evaluation along with regular motivational counseling for improved nutrition and physical activity. Study parameters were assessed at baseline and 6 months with paired t-tests used to evaluate changes after the intervention. RESULTS: The mental component summary score assessed by SF-36V2 improved significantly after program completion (45.0 to 48.8, effect size 0.37, p = 0.017), however the physical component summary score declined (46.2 to 40.9, effect size - 0.53, p = 0.004). Despite this decline in perceived physical health, markers of health-related fitness and nutritional status were maintained or improved. Systolic and diastolic blood pressure also improved after the intervention (136.7 to 124.1 mmHg, p = 0.001 and 84.0 to 78.7 mmHg, p = 0.031, respectively). No significant change in resting heart rate, body mass index, lipids, hemoglobin A1C, or left ventricular ejection fraction was observed. CONCLUSIONS:Patient-reported mental health improved significantly in women with BCA enrolled in a comprehensive CVD risk reduction program despite exposure to potentially cardiotoxic therapies. This study provides preliminary data for future randomized controlled trials evaluating the effects CVD risk reduction program in high-risk breast cancer cohorts.
Entities:
Keywords:
Behavioral health; Breast cancer; Cardio-oncology; Cardiotoxicity; Cardiovascular
Authors: Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani Journal: Circulation Date: 2019-03-05 Impact factor: 29.690
Authors: Laxmi S Mehta; Karol E Watson; Ana Barac; Theresa M Beckie; Vera Bittner; Salvador Cruz-Flores; Susan Dent; Lavanya Kondapalli; Bonnie Ky; Tochukwu Okwuosa; Ileana L Piña; Annabelle Santos Volgman Journal: Circulation Date: 2018-02-01 Impact factor: 29.690
Authors: Susan C Gilchrist; Ana Barac; Philip A Ades; Catherine M Alfano; Barry A Franklin; Lee W Jones; Andre La Gerche; Jennifer A Ligibel; Gabriel Lopez; Kushal Madan; Kevin C Oeffinger; Jeannine Salamone; Jessica M Scott; Ray W Squires; Randal J Thomas; Diane J Treat-Jacobson; Janet S Wright Journal: Circulation Date: 2019-05-21 Impact factor: 29.690
Authors: Saro H Armenian; Christina Lacchetti; Ana Barac; Joseph Carver; Louis S Constine; Neelima Denduluri; Susan Dent; Pamela S Douglas; Jean-Bernard Durand; Michael Ewer; Carol Fabian; Melissa Hudson; Mariell Jessup; Lee W Jones; Bonnie Ky; Erica L Mayer; Javid Moslehi; Kevin Oeffinger; Katharine Ray; Kathryn Ruddy; Daniel Lenihan Journal: J Clin Oncol Date: 2016-12-05 Impact factor: 44.544
Authors: Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella Journal: Circulation Date: 2005-02-08 Impact factor: 29.690
Authors: Kim M Gans; Elizabeth Ross; Claudia W Barner; Judith Wylie-Rosett; Jerome McMurray; Charles Eaton Journal: J Nutr Date: 2003-02 Impact factor: 4.798
Authors: James MacLeod; Mohamed Abdelrahim; Sabrina Painter; Ragasnehith Maddula; Austin Steward; Abdulaziz Hamid; Richard K Cheng; Vlad Zaha; Daniel Addison; Brenton Bauer; Sherry-Ann Brown Journal: Front Cardiovasc Med Date: 2022-09-30